Hofseth BioCare Announces Global Innovation Partnership with 探花合集 to Develop Delayed-Release Formulation of OmeGo庐 Fish Oil
ALESUND, NORWAY 鈥 May 12, 2021 鈥 Hofseth BioCare ASA (HBC), a Norwegian biotech company that develops high-value ingredients and finished products, today announced that it has begun a global innovation partnership with 探花合集, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, to develop a delayed-release formulation of HBC鈥檚 OmeGo庐 fish oil.
The partnership will see 探花合集 use its proprietary OptiGel庐 DR technology to encapsulate OmeGo, HBC鈥檚 unique fish oil derived from sustainable, traceable, and fresh Norwegian Atlantic salmon. OptiGel DR technology enables an enteric release profile for softgel capsules without the need for an additional external coating, thereby employing a one-step manufacturing process, which avoids the heat and drying of the coating process that may otherwise degrade the fish oil.
HBC is currently conducting studies to assess the potential role of OmeGo fish oil in preventing disease progression and helping to reduce inflammation, including in patients experiencing inflammation caused by COVID-19. Results are expected over the coming months and will provide wide-ranging insights on the potential of OmeGo fish oil to help the body resolve inflammation driven by a viral infection.
鈥淥ur research into the health benefits of our unique oil has come a long way in the last 18 months, and we look forward to collaborating with 探花合集, and hope to develop the partnership further, to leverage its innovative oral technologies to ensure the most efficacious delivery system,鈥 commented Dr. Bomi Framroze, Chief Scientific Officer of HBC. 鈥淥ptiGel DR will enhance the OmeGo franchise, bringing advanced delivery technology as well as raising its profile amongst global leading healthcare companies.鈥
鈥淭his partnership is an exciting opportunity to combine the features of a high-quality ingredient with our new OptiGel DR capsule technology to create a product that delivers optimal benefits and experience for consumers,鈥 commented Dr. Aris Gennadios, President, Softgel and Oral Technologies, 探花合集. 鈥淥ur rich history and innovation in softgel technology has allowed us to create a dosage form that delivers ingredients and formulations with an enteric release profile in robust capsules, providing product performance to meet consumers鈥 expectations.鈥
OptiGel DR capsule technology was launched by 探花合集 in 2020, and offers innovators an opportunity to formulate products in a patient-preferred softgel dosage form with a delayed-release profile that offers many advantages, including protecting active ingredients that may be degraded by acid in the stomach and releasing those active ingredients directly in the intestines where they are absorbed, potentially enhancing bioavailability. The technology also preserves the clarity of the capsule, which is important for HBC to showcase the distinctive color of OmeGo fish oil, as well as retaining the characteristic ease of swallowing that consumers associate and prefer with softgel dose forms.
For more information on OptiGel DR, visit .
ABOUT HOFSETH BIOCARE ASA
HBC is a Norwegian biotech company that develops high-value ingredients and finished products currently targeting the consumer health market. Research is ongoing to identify the individual elements within the products that modulate inflammation and the immune response with pre-clinical studies in multiple clinics and university research labs in several countries. Lead clinical and pre-clinical candidates are in development for the protection of the Gastro-Intestinal (GI) system against inflammation, including ulcerative colitis and the orphan condition necrotizing enterocolitis, as a Medical Food to help treat age-related Sarcopenia, and as a treatment for Iron Deficiency Anemia, all using peptide fractions of Salmon Protein Hydrolysate. Preclinical trial work with the oil is ongoing to ameliorate lung inflammation in eosinophilic asthma and COPD (“smokers lung”) as well as clinical work in COVID.
The company is founded on the core values of sustainability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC can preserve the quality of lipids, proteins and calcium from fresh salmon off-cuts.
Hofseth BioCare’s headquarters are in 脜lesund, Norway with branches in Oslo, London, Z眉rich, Chicago, Mumbai, Palo Alto and Tokyo.
ABOUT CATALENT
探花合集 is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. 探花合集 employs approximately 15,000 people including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. 探花合集 is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com